This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m suffering
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Greetings from
SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat
SAN FRANCISCO — Biogen would like to make additional biotech acquisitions in 2025 beyond Friday’s offer to buy its financially troubled partner Sage Therapeutics, chief
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Here we
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Osteogenesis imperfecta, or OI, is a group of genetic
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. In this, my
Remi Barbier, the former — and currently disgraced — CEO of Cassava Sciences, is the Worst Biopharma CEO of 2024. He’s also the easiest, most
I’m not naming a Best Biopharma CEO this year. I tried — doing so, after all, is an annual exercise — but in a year in
Investors in the biotech startup Padlock Therapeutics have accused Bristol Myers Squibb of reneging on payments of up to $450 million that were negotiated as